Disease characteristics and management of hospitalised adolescents and adults with community-acquired pneumonia in China: a retrospective multicentre survey

BMJ Open. 2018 Feb 15;8(2):e018709. doi: 10.1136/bmjopen-2017-018709.

Abstract

Objectives: To describe the clinical characteristics and management of patients hospitalised with community-acquired pneumonia (CAP) in China.

Design: This was a multicentre, retrospective, observational study.

Setting: 13 teaching hospitals in northern, central and southern China from 1 January 2014 to 31 December 2014 PARTICIPANTS: Information on hospitalised patients aged ≥14 years with radiographically confirmed pneumonia with illness onset in the community was collected using standard case report forms.

Primary and secondary outcome measures: Resource use for CAP management.

Results: Of 14 793 patients screened, 5828 with radiographically confirmed CAP were included in the final analysis. Low mortality risk patients with a CURB-65 score 0-1 and Pneumonia Severity Index risk class I-II accounted for 81.2% (4434/5594) and 56.4% (2034/3609) patients, respectively. 21.7% (1111/5130) patients had already achieved clinical stability on admission. A definite or probable pathogen was identified only in 12.7% (738/5828) patients. 40.9% (1575/3852) patients without pseudomonal infection risk factors received antimicrobial overtreatment regimens. The median duration between clinical stability to discharge was 5.0 days with 30-day mortality of 4.2%.

Conclusions: These data demonstrated the overuse of health resources in CAP management, indicating that there is potential for improvement and substantial savings to healthcare systems in China.

Trial registration number: NCT02489578; Results.

Keywords: China; community-acquired pneumonia; disease characteristics; management.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / economics
  • Anti-Bacterial Agents / therapeutic use*
  • China
  • Community-Acquired Infections / drug therapy
  • Community-Acquired Infections / economics
  • Community-Acquired Infections / microbiology
  • Community-Acquired Infections / therapy*
  • Female
  • Health Care Costs
  • Health Resources / statistics & numerical data*
  • Hospitalization* / economics
  • Hospitals, Teaching
  • Humans
  • Length of Stay / economics
  • Male
  • Medical Overuse* / economics
  • Middle Aged
  • Pneumonia / drug therapy
  • Pneumonia / economics
  • Pneumonia / microbiology
  • Pneumonia / therapy*
  • Pseudomonas / growth & development
  • Pseudomonas Infections / drug therapy
  • Pseudomonas Infections / economics
  • Pseudomonas Infections / microbiology
  • Pseudomonas Infections / therapy
  • Retrospective Studies
  • Risk Factors
  • Severity of Illness Index*
  • Surveys and Questionnaires
  • Young Adult

Substances

  • Anti-Bacterial Agents

Associated data

  • ClinicalTrials.gov/NCT02489578
  • ClinicalTrials.gov/NCT02489578